You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
|
|---|---|
| Published in |
Frontiers in oncology, February 2023
|
| DOI | 10.3389/fonc.2023.1069370 |
| Pubmed ID | |
| Authors |
Giulia Martini, Davide Ciardiello, Stefania Napolitano, Erika Martinelli, Teresa Troiani, Tiziana Pia Latiano, Antonio Avallone, Nicola Normanno, Massimo Di Maio, Evaristo Maiello, Fortunato Ciardiello |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 4 | 57% |
| Netherlands | 1 | 14% |
| United States | 1 | 14% |
| Unknown | 1 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 43% |
| Members of the public | 2 | 29% |
| Practitioners (doctors, other healthcare professionals) | 1 | 14% |
| Science communicators (journalists, bloggers, editors) | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 1 | 13% |
| Student > Bachelor | 1 | 13% |
| Researcher | 1 | 13% |
| Lecturer | 1 | 13% |
| Unknown | 4 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 1 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 13% |
| Computer Science | 1 | 13% |
| Medicine and Dentistry | 1 | 13% |
| Unknown | 4 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2023.
All research outputs
#7,857,016
of 25,394,764 outputs
Outputs from Frontiers in oncology
#2,814
of 22,436 outputs
Outputs of similar age
#151,572
of 487,183 outputs
Outputs of similar age from Frontiers in oncology
#125
of 1,474 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 22,436 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 487,183 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 1,474 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.